Apimeds Pharmaceuticals US (APUS) Other Non-Current Assets (2025)

Apimeds Pharmaceuticals US (APUS) posted Other Non-Current Assets of $75485.0 for Q4 2025, down 41.82% on a QoQ basis from $129740.0 in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Other Non-Current Assets (2025) Analysis & Trends

Apimeds Pharmaceuticals US's Other Non-Current Assets history runs 1 years deep, the most recent figure standing at $75485.0 for Q4 2025.

Quarterly Other Non-Current Assets changed N/A year-over-year to $75485.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $75485.0 (changed N/A YoY) and the FY2025 annual result came in at $75485.0, changed N/A from the prior year.
Other Non-Current Assets was $75485.0 for Q4 2025 at Apimeds Pharmaceuticals US, down from $129740.0 in the prior quarter.
Across five years, Other Non-Current Assets topped out at $183995.0 in Q2 2025 and bottomed at $75485.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Haleon	87.22 Bn	85.35 Bn	-	49.22 Mn
2	Teva Pharmaceutical Industries	39.60 Bn	35.87 Bn	1.97 Bn	1.79 Bn
3	Zoetis	31.46 Bn	29.52 Bn	1.62 Bn	351.00 Mn
4	Takeda Pharmaceutical	26.49 Bn	22.44 Bn	4.39 Bn	491.06 Mn
5	United Therapeutics	23.03 Bn	20.88 Bn	648.10 Mn	233.20 Mn
6	Universe Pharmaceuticals	23.03 Bn	-10.56 Bn	-	-
7	Viatris	20.90 Bn	19.09 Bn	1.16 Bn	1.11 Bn
8	Neurocrine Biosciences	17.50 Bn	16.19 Bn	800.70 Mn	73.60 Mn
9	Elanco Animal Health	12.33 Bn	11.91 Bn	785.00 Mn	295.00 Mn
10	Apimeds Pharmaceuticals US	8.17 Mn	8.17 Mn	-	75,485.00

Download Data